Literature DB >> 23099250

Semaphorins in cancer: biological mechanisms and therapeutic approaches.

Michael Rehman1, Luca Tamagnone.   

Abstract

The hallmarks of cancer include multiple alterations in the physiological processes occurring in normal tissues, such as cell proliferation, apoptosis, and restricted cell migration. These aberrant behaviors are due to genetic and epigenetic changes that affect signaling pathways controlling cancer cells, as well as the surrounding "normal" cells in the tumor microenvironment. Semaphorins and their receptors (mainly plexins and neuropilins) are aberrantly expressed in human tumors, and multiple family members are emerging as pivotal signals deregulated in cancer. Notably, different semaphorins can promote or inhibit tumor progression, depending on the implicated receptor complexes and responsive cell type. The important role of semaphorin signals in the regulation of tumor angiogenesis, invasion and metastasis has initiated multiple experimental approaches aimed at targeting these pathways to inhibit cancer.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23099250     DOI: 10.1016/j.semcdb.2012.10.005

Source DB:  PubMed          Journal:  Semin Cell Dev Biol        ISSN: 1084-9521            Impact factor:   7.727


  44 in total

1.  Neuropilin-2 Is upregulated in lung cancer cells during TGF-β1-induced epithelial-mesenchymal transition.

Authors:  Patrick Nasarre; Robert M Gemmill; Vincent A Potiron; Joëlle Roche; Xian Lu; Anna E Barón; Christopher Korch; Elizabeth Garrett-Mayer; Alessandro Lagana; Philip H Howe; Harry A Drabkin
Journal:  Cancer Res       Date:  2013-10-11       Impact factor: 12.701

2.  Downregulation of Semaphorin-3F is associated with poor prognostic significance in osteosarcoma patients.

Authors:  Ming-Han Liu; Wen-Juan Fu; You-Hong Cui; Qiao-Nan Guo; Yue Zhou
Journal:  Am J Cancer Res       Date:  2016-10-01       Impact factor: 6.166

Review 3.  Tumor progression: the neuronal input.

Authors:  Marco Arese; Federico Bussolino; Margherita Pergolizzi; Laura Bizzozero; Davide Pascal
Journal:  Ann Transl Med       Date:  2018-03

4.  Sema4C/PlexinB2 signaling controls breast cancer cell growth, hormonal dependence and tumorigenic potential.

Authors:  Sreeharsha Gurrapu; Emanuela Pupo; Giulia Franzolin; Letizia Lanzetti; Luca Tamagnone
Journal:  Cell Death Differ       Date:  2018-03-19       Impact factor: 15.828

Review 5.  Transmembrane semaphorins, forward and reverse signaling: have a look both ways.

Authors:  Chiara Battistini; Luca Tamagnone
Journal:  Cell Mol Life Sci       Date:  2016-01-21       Impact factor: 9.261

Review 6.  Transmembrane semaphorins: Multimodal signaling cues in development and cancer.

Authors:  Sreeharsha Gurrapu; Luca Tamagnone
Journal:  Cell Adh Migr       Date:  2016-06-13       Impact factor: 3.405

7.  Semaphorin 3D autocrine signaling mediates the metastatic role of annexin A2 in pancreatic cancer.

Authors:  Kelly Foley; Agnieszka A Rucki; Qian Xiao; Donger Zhou; Ashley Leubner; Guanglan Mo; Jennifer Kleponis; Annie A Wu; Rajni Sharma; Qingguang Jiang; Robert A Anders; Christine A Iacobuzio-Donahue; Katherine A Hajjar; Anirban Maitra; Elizabeth M Jaffee; Lei Zheng
Journal:  Sci Signal       Date:  2015-08-04       Impact factor: 8.192

8.  A simple and efficient method for generating high-quality recombinant Mical enzyme for in vitro assays.

Authors:  Heng Wu; Ruei-Jiun Hung; Jonathan R Terman
Journal:  Protein Expr Purif       Date:  2016-05-17       Impact factor: 1.650

9.  Knocking Out SST Gene of BGC823 Gastric Cancer Cell by CRISPR/Cas9 Enhances Migration, Invasion and Expression of SEMA5A and KLF2.

Authors:  Wei Chen; Ruixian Ding; Jinlu Tang; Haodong Li; Chonghua Chen; Yaru Zhang; Qinxian Zhang; Xiaoyan Zhu
Journal:  Cancer Manag Res       Date:  2020-02-20       Impact factor: 3.989

10.  Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium.

Authors:  Sharon E Johnatty; Jonathan P Tyrer; Siddhartha Kar; Jonathan Beesley; Yi Lu; Bo Gao; Peter A Fasching; Alexander Hein; Arif B Ekici; Matthias W Beckmann; Diether Lambrechts; Els Van Nieuwenhuysen; Ignace Vergote; Sandrina Lambrechts; Mary Anne Rossing; Jennifer A Doherty; Jenny Chang-Claude; Francesmary Modugno; Roberta B Ness; Kirsten B Moysich; Douglas A Levine; Lambertus A Kiemeney; Leon F A G Massuger; Jacek Gronwald; Jan Lubiński; Anna Jakubowska; Cezary Cybulski; Louise Brinton; Jolanta Lissowska; Nicolas Wentzensen; Honglin Song; Valerie Rhenius; Ian Campbell; Diana Eccles; Weiva Sieh; Alice S Whittemore; Valerie McGuire; Joseph H Rothstein; Rebecca Sutphen; Hoda Anton-Culver; Argyrios Ziogas; Simon A Gayther; Aleksandra Gentry-Maharaj; Usha Menon; Susan J Ramus; Celeste L Pearce; Malcolm C Pike; Daniel O Stram; Anna H Wu; Jolanta Kupryjanczyk; Agnieszka Dansonka-Mieszkowska; Iwona K Rzepecka; Beata Spiewankiewicz; Marc T Goodman; Lynne R Wilkens; Michael E Carney; Pamela J Thompson; Florian Heitz; Andreas du Bois; Ira Schwaab; Philipp Harter; Jacobus Pisterer; Peter Hillemanns; Beth Y Karlan; Christine Walsh; Jenny Lester; Sandra Orsulic; Stacey J Winham; Madalene Earp; Melissa C Larson; Zachary C Fogarty; Estrid Høgdall; Allan Jensen; Susanne Kruger Kjaer; Brooke L Fridley; Julie M Cunningham; Robert A Vierkant; Joellen M Schildkraut; Edwin S Iversen; Kathryn L Terry; Daniel W Cramer; Elisa V Bandera; Irene Orlow; Tanja Pejovic; Yukie Bean; Claus Høgdall; Lene Lundvall; Ian McNeish; James Paul; Karen Carty; Nadeem Siddiqui; Rosalind Glasspool; Thomas Sellers; Catherine Kennedy; Yoke-Eng Chiew; Andrew Berchuck; Stuart MacGregor; Paul D P Pharoah; Ellen L Goode; Anna deFazio; Penelope M Webb; Georgia Chenevix-Trench
Journal:  Clin Cancer Res       Date:  2015-07-07       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.